AngioDynamics Inc - Company Profile
Powered by 
All the sales intelligence you need on AngioDynamics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how AngioDynamics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with AngioDynamics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
AngioDynamics Inc (AngioDynamics) designs, manufactures and markets minimally invasive and image-guided therapeutics and diagnostic devices. Its product portfolio encompasses vascular products, radiofrequency ablation and NanoKnife systems, vascular access products, angiographic products and accessories, products for dialysis, angioplasty, drainage, thrombolysis and embolization, as well as venous products and renal therapy products. The company’s products find application in interventional radiology, interventional cardiology, and minimally invasive diagnosis and treatment of cancer and peripheral vascular disease. It sells its products through direct sales force in the US and through a network of distributors outside the US, which include Latin America, Europe, Asia, and others. AngioDynamics is headquartered in Latham, New York, the US.
Headquarters
United States of America
Address
14 Plaza Drive, Latham, New York, 12110
Website
www.angiodynamics.com
Telephone
1 800 7726446
No of Employees
632
Industry
Medical Equipment
Ticker Symbol & Exchange
ANGO (NASD)
Revenue (2025)
$320.2M
9.5%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-8.1%
(2025 vs 2024)
Market Cap*
$635.3M
Net Profit Margin (2025)
XYZ
1.2%
(2025 vs 2024)
* As of and is in US$
AngioDynamics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Ablation: | Auryon |
| NanoKnife System | AlphaVac |
| Solero Microwave Tissue Ablation System | AngioVac |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Asset Disposal | In June, the company sold a portfolio of dialysis catheter products and the BioSentry Biopsy Tract Sealant System to Merit Medical Systems, Inc., a manufacturer and marketer of healthcare technology. |
| 2023 | Contracts/Agreements | In April, the company and Cardiva announced their partnership to distribute the company’s Oncology portfolio in Europe. |
| 2023 | Contracts/Agreements | In March, the company announced several new partnerships with AddLife in various markets including UK, Ireland and Nordic markets to distribute its oncology and surgical products in these markets. |
Competitor Comparison
| Key Parameters | AngioDynamics Inc | Johnson & Johnson | Medtronic Plc | Boston Scientific Corp | Varian Medical Systems Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Ireland | United States of America | United States of America |
| City | Latham | New Brunswick | Dublin | Marlborough | Palo Alto |
| State/Province | New York | New Jersey | - | Massachusetts | California |
| No. of Employees | 632 | 138,200 | 95,000 | 59,000 | 10,000 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Howard W. Donnelly | Chairman | Executive Board | 2004 | 64 |
| James C. Clemmer | President; Chief Executive Officer; Director | Executive Board | 2016 | 61 |
| Stephen A. Trowbridge | Executive Vice President; Chief Financial Officer | Senior Management | 2020 | 51 |
| Lawrence T. Weiss | Chief Legal Officer; Secretary; Senior Vice President | Senior Management | 2024 | 57 |
| Warren G. Nighan | Senior Vice President - Global Supply Chain, Quality and Regulatory Affairs | Senior Management | 2017 | 57 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer